相关实验视频
Updated: Jul 17, 2026

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
在遗传ALS中,发病和进展由运动神经元和微质决定
Séverine Boillée1, Koji Yamanaka, Christian S Lobsiger
1Ludwig Institute for Cancer Research and Departments of Medicine and Neuroscience, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
概括
超氧化物失突酶中占主导地位的突变会导致肌缩性侧面硬化症 (ALS). 运动神经元中的突变基因表达驱动早期疾病,而微质细胞的参与减缓了后来的进展,验证了基于细胞的疗法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 超氧化解突变酶 (SOD1) 中的主导突变是已知的家族性ALS的原因.
- 运动神经元损失是ALS病理学的标志.
研究的目的:
- 为了研究突变型超氧化解突变酶在ALS病变发生中的细胞特异性作用.
- 为了区分驱动ALS发病的机制与晚期疾病进展.
- 评估针对ALS不同细胞类型的治疗潜力.
主要方法:
- 使用具有可删除突变SOD1基因的转基因小鼠.
- 在运动神经元和微质中操纵突变基因表达.
- 观察到对疾病发病和进展时间表的影响.
主要成果:
- 突变SOD1的运动神经元表达对ALS发病和早期进展至关重要.
- 降低微质中的突变SOD1水平显著减缓了晚期疾病进展.
- 这些发现凸显了细胞对ALS病变的独特贡献.
结论:
- 发病和进展是不同的阶段,由突变SOD1在不同细胞类型中驱动.
- 运动神经元是早期疾病的关键驱动因素,而微质细胞则影响后期阶段.
- 针对非神经元细胞的疗法,如微质细胞,显示出减缓ALS进展的希望.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

